CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
RegSign aims to improve cancer immunotherapy by studying regulatory T cells (Tregs) and their role in immune responses. The project seeks to develop predictive biomarkers and therapeutic strategies to enhance treatment efficacy while minimizing adverse effects associated with immunotherapy.
The advent of immune checkpoint inhibitors (ICI), that target regulatory pathways in T cells to unleash antitumor immune responses, has revolutionized cancer immunotherapy.
However, despite the enormous success of ICI in the treatment of cancer, a significant proportion of patients do not respond, while responses are frequently accompanied by life-threatening autoimmune related adverse events (irAEs).
Predictive biomarkers of clinical responses and new therapeutic strategies to harness anti-tumo…
BIOMEDICAL RESEARCH FOUNDATION, ACADEMY OF ATHENS
IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
